Metoprolol is formally classified as an antiarrhythmic drug. It belongs to Class II of the Vaughan-Williams system, the standard framework cardiologists use to categorize drugs that treat abnormal heart rhythms. That said, most people think of “antiarrhythmics” as drugs like amiodarone or flecainide, which act directly on ion channels in the heart muscle. Metoprolol works differently, blocking the effects of adrenaline on the heart, and this distinction matters in practice because it shapes which arrhythmias metoprolol handles well and which ones call for something stronger.
Where Metoprolol Sits in the Antiarrhythmic Classification
The Vaughan-Williams system divides antiarrhythmic drugs into four classes based on how they affect the heart’s electrical activity. Class I drugs block sodium channels. Class III drugs block potassium channels. Class IV drugs block calcium channels. Class II is the beta-blocker group, and metoprolol is one of its most widely prescribed members.1PubMed. Antiarrhythmic agents: drug interactions of clinical significance So yes, by any standard pharmacology reference, metoprolol is an antiarrhythmic. But this classification can be misleading, because beta-blockers occupy a unique niche. They do not primarily act by altering the electrical properties of heart cells the way sodium or potassium channel blockers do. Instead, they dampen the sympathetic nervous system’s ability to speed up and destabilize the heart. The practical result is a drug that prevents arrhythmias in certain situations and controls the heart rate during others, but rarely terminates a dangerous rhythm on its own the way a Class I or Class III drug might.
How Metoprolol Actually Affects Heart Rhythm
Your heart speeds up when adrenaline (and its cousin noradrenaline) binds to beta-adrenergic receptors on heart cells. Metoprolol blocks those receptors selectively, particularly in the heart. The immediate effect is a slower heart rate and reduced force of contraction, which lowers the heart’s oxygen demand.2Heart Failure Reviews. Biologic rationale for the use of beta-blockers in the treatment of heart failure But there is a subtler electrical effect. Over time, metoprolol prolongs the refractory period of heart tissue, meaning cells take longer to “reset” after each beat and become available for the next electrical impulse. Animal studies after heart attacks found that metoprolol extended repolarization beyond what the injury alone caused, and researchers believe this longer refractory period helps counteract fast, chaotic rhythms.3PubMed. Effects of metoprolol and ramipril on action potentials after myocardial infarction in rats This effect appears to be a property of long-term beta-blocker use rather than an immediate pharmacological action, which helps explain why metoprolol’s antiarrhythmic benefits often emerge over weeks rather than minutes.4The American Journal of Cardiology. Electrophysiologic effects of beta blockers in ventricular arrhythmias
Metoprolol also slows electrical conduction through the AV node, the gateway between the upper and lower chambers of the heart. During atrial fibrillation, when the upper chambers fire chaotically at rates of 300 or more impulses per minute, the AV node decides how many of those impulses reach the ventricles. Metoprolol increases the AV node’s refractory period, acting as a gatekeeper that lets fewer impulses through and keeps the ventricular rate from spiraling dangerously high.5PubMed. Non-invasive evaluation of the effect of metoprolol on the atrioventricular node during permanent atrial fibrillation
Controlling Heart Rate in Atrial Fibrillation
Atrial fibrillation is the most common sustained arrhythmia, and metoprolol is one of the first drugs reached for when the heart rate is racing. It is important to be clear about what metoprolol does here: it controls the rate rather than restoring a normal rhythm. The atria keep fibrillating, but the ventricles slow down to a safer pace. This is called rate control, and it is the cornerstone of AF management for many patients.
How well does metoprolol compare to the other go-to rate-control drug, diltiazem? A meta-analysis of randomized and observational studies found that intravenous diltiazem was significantly more effective than intravenous metoprolol for achieving heart rate control in randomized trials, though this advantage was less clear in observational data.6PubMed. Intravenous Diltiazem Versus Metoprolol in Acute Rate Control of Atrial Fibrillation/Flutter and Rapid Ventricular Response: A Meta-Analysis of Randomized and Observational Studies One prospective trial illustrated the gap starkly: within five minutes of drug administration, half the patients receiving diltiazem reached a target heart rate below 100, compared with roughly one in ten on metoprolol. By 30 minutes, the diltiazem group had a success rate above 95%, while metoprolol reached under half.7PubMed Central. A Systematic Review of Weight-Based Metoprolol for Acute Atrial Fibrillation with Rapid Ventricular Rate That sounds like a blowout, but context matters. A separate retrospective study found no significant difference in rate control between the two drugs, with about 35% of metoprolol patients and 41% of diltiazem patients achieving control.8PubMed. Intravenous Metoprolol Versus Diltiazem for Rate Control in Atrial Fibrillation Dosing, patient selection, and how sick the patients were likely explain the gap between studies.
The practical takeaway: diltiazem tends to work faster and more reliably in an emergency setting, but metoprolol remains a solid option, especially for patients who also have heart failure or reduced heart function, where diltiazem can be harmful.
Preventing Arrhythmias After Heart Surgery
Atrial fibrillation after cardiac surgery is extremely common, affecting roughly a quarter or more of patients. It lengthens hospital stays, raises costs, and increases stroke risk. Metoprolol has been studied extensively for prevention in this setting, and the evidence is encouraging. A systematic review and meta-analysis found that metoprolol is effective at preventing post-operative atrial fibrillation compared with placebo and performed similarly to Class III antiarrhythmic drugs.9PubMed Central. Metoprolol for prophylaxis of postoperative atrial fibrillation in cardiac surgery patients: systematic review and meta-analysis
A head-to-head randomized trial compared metoprolol directly with amiodarone, one of the most potent antiarrhythmics available, for preventing AF after cardiac surgery. Atrial fibrillation occurred in about 24% of the metoprolol group and 25% of the amiodarone group, a negligible difference.10PubMed. Metoprolol versus amiodarone in the prevention of atrial fibrillation after cardiac surgery: a randomized trial This is a striking finding because amiodarone is considered one of the most powerful rhythm drugs available, with a long list of potential side effects including thyroid dysfunction and lung toxicity. The fact that metoprolol matched it for post-surgical AF prevention, with a generally milder side-effect profile, is a real point in its favor. One study did note that perioperative metoprolol carries a meaningful risk of bradycardia (excessively slow heart rate), so monitoring remains important.11PubMed. Prophylaxis against atrial fibrillation after cardiac surgery: beneficial effect of perioperative metoprolol
Ventricular Arrhythmias and Sudden Death
This is where metoprolol’s antiarrhythmic credentials get most serious. Ventricular arrhythmias, including premature ventricular contractions (PVCs), ventricular tachycardia, and ventricular fibrillation, can be life-threatening. Early research found that metoprolol at 200 mg per day suppressed about 60% of total premature ventricular beats, with ventricular tachycardia episodes dropping by 94%.12PubMed. Evaluation of metoprolol in suppressing complex ventricular arrhythmias That said, metoprolol is not the strongest option for every patient with troublesome PVCs. A recent pediatric crossover trial found that flecainide reduced PVC burden by about 10.6 percentage points compared with 2.4 percentage points for metoprolol, a significant difference.13PubMed. ECTOPIC trial: The efficacy of flEcainide Compared To metOprolol in reducing Premature ventrIcular Contractions
Where metoprolol truly shines is in reducing sudden cardiac death among heart failure patients. The landmark MERIT-HF trial enrolled thousands of patients with symptomatic heart failure and randomized them to metoprolol succinate (the extended-release form) or placebo. The trial was stopped early because the benefit was so clear. Sudden deaths dropped by 41%, deaths from worsening heart failure fell by 49%, and overall cardiovascular death was reduced by 38%.14PubMed. MERIT-HF mortality and morbidity data These reductions are enormous by the standards of heart failure trials, and sudden death in heart failure is almost always caused by ventricular arrhythmias. In this population, metoprolol’s antiarrhythmic effect translates directly into lives saved. Separately, in the CASH trial comparing treatments after cardiac arrest, the effect of amiodarone on all-cause mortality was comparable to that of metoprolol, reinforcing that beta-blockers hold their own against more traditional antiarrhythmics even in the highest-risk patients.15JAMA. Prescribing Amiodarone: An Evidence-Based Review of Clinical Indications
Supraventricular Tachycardia
Supraventricular tachycardia (SVT) is a broad term for fast rhythms that originate above the ventricles. Metoprolol has been used both to terminate SVT episodes and to prevent recurrences, with mixed results. When given intravenously during sustained SVT, metoprolol terminated the arrhythmia in about a third of cases in one early study. On longer-term oral treatment, roughly half of patients remained free of SVT attacks over several months, while the rest continued to have episodes.16PubMed. Metoprolol in the treatment and prophylaxis of paroxysmal reentrant supraventricular tachycardia
After coronary artery bypass surgery, SVT is a common complication, and here metoprolol appears less effective than sotalol, a beta-blocker that also has Class III antiarrhythmic properties. One trial found that SVT terminated in an average of about 2.4 hours with sotalol compared with over 13 hours with metoprolol.17PubMed. Prevention and treatment of supraventricular tachycardia shortly after coronary artery bypass grafting: a randomized open trial Sotalol’s dual mechanism, combining beta-blockade with potassium channel blockade, gives it an edge for acute rhythm conversion. Metoprolol is better thought of as a preventive agent and rate-control tool rather than a first-choice drug for terminating SVT on the spot.
The Long QT Syndrome Exception
Not all arrhythmia conditions respond equally to metoprolol, and long QT syndrome is a cautionary example. Long QT syndrome is an inherited condition where the heart’s electrical recovery takes abnormally long, predisposing patients to dangerous ventricular arrhythmias. Beta-blockers are the mainstay of treatment, but not all beta-blockers perform the same.
A study published in the Journal of the American College of Cardiology found that symptomatic patients with long QT syndrome who were started on metoprolol had roughly four times the odds of experiencing a breakthrough cardiac event compared with those on propranolol or nadolol.18PubMed Central. Not all Beta-Blockers are Equal in the Management of Long QT Syndrome Types 1 and 2: Higher Recurrence of Events under Metoprolol A network meta-analysis added nuance: metoprolol showed a clear risk-reducing effect in patients with the LQT1 subtype but failed to show a significant benefit in LQT2.19Frontiers in Pharmacology. The Efficacy of Beta-Blockers in Patients With Long QT Syndrome 1–3 According to Individuals’ Gender, Age, and QTc Intervals: A Network Meta-analysis The clinical consensus that has emerged is that propranolol and nadolol are preferred over metoprolol for long QT syndrome. If you have been diagnosed with this condition and are taking metoprolol, it is worth raising the question with your cardiologist.
Tartrate Versus Succinate
Metoprolol comes in two forms that are not interchangeable, and the distinction matters for arrhythmia management. Metoprolol tartrate is short-acting and typically taken twice daily. Metoprolol succinate is a longer-acting salt formulated for once-daily dosing.20PubMed. Pharmacokinetics and pharmacodynamics of beta blockers in heart failure The MERIT-HF trial that demonstrated the dramatic reductions in sudden death used metoprolol succinate specifically.21American College of Cardiology. Metoprolol CR/XL Randomized Intervention Trial in Congestive Heart Failure – MERIT-HF A comparative analysis of beta-blockers in heart failure ranked metoprolol succinate as comparable in effectiveness to carvedilol and nebivolol, and superior to metoprolol tartrate.22PubMed Central. Effectiveness and safety of four different beta-blockers in patients with chronic heart failure
If you are taking metoprolol for a rhythm-related condition, the formulation matters. Tartrate has peaks and troughs in blood levels that can leave you less protected at certain hours. Succinate provides steadier coverage. Guidelines for heart failure specifically recommend the succinate form, and many cardiologists prefer it for arrhythmia prevention as well.
Combining Metoprolol With Other Antiarrhythmics
Metoprolol is frequently prescribed alongside amiodarone, particularly in patients with both heart failure and difficult-to-control arrhythmias. This combination makes pharmacological sense since the two drugs act through different mechanisms, but it also introduces risks. Amiodarone inhibits the liver enzyme that breaks down metoprolol, which can raise metoprolol levels in the blood and increase the chance of excessive heart-rate slowing or AV block.23PubMed Central. Impact of amiodarone use on metoprolol concentrations, α‐OH ‐metoprolol concentrations, metoprolol dosing and heart rate: A cross‐sectional study
Despite this interaction, the combination appears to be beneficial when managed carefully. A study of patients with coronary heart disease complicated by arrhythmias found that the amiodarone-metoprolol combination improved cardiac function, heart rate variability, and multiple electrical parameters more than either drug alone, with fewer adverse events in the combination group.24PubMed Central. Amiodarone combined with metoprolol improves cardiac function in patients with coronary heart disease complicated by arrhythmia Lab studies in isolated rat hearts also found that adding amiodarone to metoprolol did not worsen the heart-slowing effect or depress the heart’s pumping ability compared with metoprolol alone, and it actually increased blood flow through the coronary arteries.25PubMed Central. Effects of metoprolol and amiodarone combination on heart rate, myocardial contractility and coronary flow: Study in isolated perfused rat hearts The takeaway is that the combination can work well, but it requires dose adjustments and close monitoring of heart rate.
The Role of the Nervous System
One underappreciated aspect of metoprolol’s antiarrhythmic activity involves the brain. Unlike atenolol, another common beta-blocker, metoprolol crosses the blood-brain barrier. This gives it access to beta receptors in the central nervous system, which play a role in the stress response. An animal study found that metoprolol, but not atenolol, prevented the stress-induced release of neuropeptide Y, a molecule that raises blood pressure for prolonged periods and dials down the calming influence of the vagus nerve on the heart.26PubMed. Metoprolol, but not atenolol, reduces stress induced neuropeptide Y release in pigs
This central nervous system effect could partly explain why metoprolol is particularly good at preventing arrhythmias triggered by emotional stress or physical exertion, situations where adrenaline surges originate in the brain before they reach the heart. It also suggests that not all beta-blockers are interchangeable for arrhythmia prevention, even if they lower heart rate by similar amounts. The ability to dampen the upstream stress signal, not just block its effect at the heart, gives metoprolol a layer of protection that purely peripheral beta-blockers lack. Research on heart failure models has similarly shown that the combination of beta-blockade with other therapies can correct abnormal calcium handling in heart cells, which is a key driver of the chaotic electrical activity that triggers ventricular arrhythmias.27BMJ Publishing Group Ltd and British Cardiovascular Society. β-Adrenergic blockade combined with subcutaneous B-type natriuretic peptide: a promising approach to reduce ventricular arrhythmia in heart failure?
When Metoprolol Is Not the Right Antiarrhythmic
Recognizing metoprolol’s limits is just as important as recognizing its strengths. If you have Wolff-Parkinson-White syndrome with an accessory pathway that conducts rapidly, beta-blockers alone are usually insufficient and catheter ablation is the preferred treatment. For sustained ventricular tachycardia in a structurally abnormal heart, metoprolol may serve as background therapy but is rarely the primary rhythm-control agent; amiodarone, lidocaine, or an implantable defibrillator typically takes that role. And as noted, patients with long QT syndrome are generally better served by propranolol or nadolol.
Metoprolol also has practical limitations. It lowers blood pressure, which can be a problem in patients who are already hypotensive from a rapid arrhythmia. It worsens bronchospasm in people with severe asthma, though the risk is lower than with non-selective beta-blockers. And it should not be stopped abruptly, because rebound sympathetic activation can actually provoke the very arrhythmias it was prescribed to prevent. Tapering over a week or two is standard practice.
The honest framing is that metoprolol is a broad, safe, well-studied antiarrhythmic with a mechanism that makes it especially effective at preventing stress- and heart-failure-related arrhythmias, but it is not designed to be a standalone fix for every disordered rhythm. It fills a role that flashier antiarrhythmics cannot, including a proven mortality benefit in heart failure that no Class I or Class III drug has matched, while leaving the heavier electrical lifting to more targeted agents when the situation demands it.